IL193315A - 5 - (Ethylsulfonyl) -2 - (Naphthalene-2-ram) benzo [d] oxazole and use in the treatment of muscular dystrophy or muscular dystrophy - Google Patents

5 - (Ethylsulfonyl) -2 - (Naphthalene-2-ram) benzo [d] oxazole and use in the treatment of muscular dystrophy or muscular dystrophy

Info

Publication number
IL193315A
IL193315A IL193315A IL19331508A IL193315A IL 193315 A IL193315 A IL 193315A IL 193315 A IL193315 A IL 193315A IL 19331508 A IL19331508 A IL 19331508A IL 193315 A IL193315 A IL 193315A
Authority
IL
Israel
Prior art keywords
muscular dystrophy
ethylsulfonyl
naphthalen
oxazole
benzo
Prior art date
Application number
IL193315A
Other languages
English (en)
Hebrew (he)
Other versions
IL193315A0 (en
Original Assignee
Summit Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0602768A external-priority patent/GB0602768D0/en
Priority claimed from GB0614690A external-priority patent/GB0614690D0/en
Priority claimed from GB0619281A external-priority patent/GB0619281D0/en
Priority claimed from GB0623983A external-priority patent/GB0623983D0/en
Application filed by Summit Corp Plc filed Critical Summit Corp Plc
Publication of IL193315A0 publication Critical patent/IL193315A0/en
Publication of IL193315A publication Critical patent/IL193315A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
IL193315A 2006-02-10 2008-08-07 5 - (Ethylsulfonyl) -2 - (Naphthalene-2-ram) benzo [d] oxazole and use in the treatment of muscular dystrophy or muscular dystrophy IL193315A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0602768A GB0602768D0 (en) 2006-02-10 2006-02-10 Treatment of muscular dystrophy
GB0614690A GB0614690D0 (en) 2006-07-24 2006-07-24 Method of treatment of duchenne muscular dystrophy
GB0619281A GB0619281D0 (en) 2006-09-29 2006-09-29 Treatment of duchenne muscular dystrophy
GB0623983A GB0623983D0 (en) 2006-11-30 2006-11-30 Treatment of duchenne muscular dystrophy
PCT/GB2007/050055 WO2007091106A2 (en) 2006-02-10 2007-02-09 Treatment of duchenne muscular dystrophy

Publications (2)

Publication Number Publication Date
IL193315A0 IL193315A0 (en) 2009-09-22
IL193315A true IL193315A (en) 2016-02-29

Family

ID=38229987

Family Applications (2)

Application Number Title Priority Date Filing Date
IL193315A IL193315A (en) 2006-02-10 2008-08-07 5 - (Ethylsulfonyl) -2 - (Naphthalene-2-ram) benzo [d] oxazole and use in the treatment of muscular dystrophy or muscular dystrophy
IL228598A IL228598A0 (en) 2006-02-10 2013-09-29 Treatment of Duchenne muscular dystrophy

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL228598A IL228598A0 (en) 2006-02-10 2013-09-29 Treatment of Duchenne muscular dystrophy

Country Status (17)

Country Link
US (2) US8518980B2 (https=)
EP (1) EP1986633B1 (https=)
JP (1) JP5376956B2 (https=)
KR (2) KR101472248B1 (https=)
AU (1) AU2007213451B2 (https=)
BR (1) BRPI0707719A2 (https=)
CA (1) CA2641880C (https=)
CY (1) CY1115657T1 (https=)
DK (1) DK1986633T3 (https=)
ES (1) ES2522290T3 (https=)
IL (2) IL193315A (https=)
MX (1) MX2008010187A (https=)
NZ (1) NZ570625A (https=)
PL (1) PL1986633T3 (https=)
PT (1) PT1986633E (https=)
SI (1) SI1986633T1 (https=)
WO (1) WO2007091106A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641880C (en) 2006-02-10 2014-09-09 Summit Corporation Plc Treatment of duchenne muscular dystrophy
TW200813035A (en) * 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
BRPI0712823A2 (pt) * 2006-06-23 2012-07-24 Abbott Lab derivados de ciclopropil amina como moduladores de receptor de histamina h3
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
AR063311A1 (es) * 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
GB0715938D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
WO2009080788A2 (en) * 2007-12-21 2009-07-02 Universite Catholique De Louvain Antibacterial agents
US20130023498A1 (en) * 2008-02-20 2013-01-24 The Wistar Institute and North Carolina State University MicroRNA Modulators and Method for Identifying and Using the Same
EP2889027B1 (en) * 2008-03-31 2020-06-17 Shiseido Co., Ltd. Oral preparation, injection preparation, external skin preparation and cosmetic method for preventing or improving wrinkles
JP5369854B2 (ja) * 2008-04-21 2013-12-18 住友化学株式会社 有害節足動物防除組成物および縮合複素環化合物
PT2280706E (pt) * 2008-05-14 2013-02-19 Otsuka Pharma Co Ltd Composições compreendendo derivados de benzeno que activam lipase de lipoproteína
AU2009260519A1 (en) * 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
GB0815369D0 (en) * 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
US8394969B2 (en) 2008-09-26 2013-03-12 Merck Sharp & Dohme Corp. Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2352374B1 (en) 2008-10-29 2014-09-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
GB0821307D0 (en) * 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2010107768A1 (en) * 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
US8969342B2 (en) * 2009-03-20 2015-03-03 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
GB0905667D0 (en) * 2009-04-02 2009-05-20 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
GB0905664D0 (en) * 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
BR112012006630A2 (pt) * 2009-09-24 2016-05-03 Hoffmann La Roche derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac)
JP5540640B2 (ja) 2009-10-07 2014-07-02 住友化学株式会社 複素環化合物及びその有害節足動物防除用途
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US8686048B2 (en) * 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
WO2011162364A1 (ja) 2010-06-23 2011-12-29 住友化学株式会社 有害節足動物防除組成物および複素環化合物
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
CN103748085A (zh) 2011-06-09 2014-04-23 诺华股份有限公司 杂环磺酰胺衍生物
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
EP2814514B1 (en) * 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
AU2013229589A1 (en) 2012-03-06 2014-09-11 Compound Handling B.V. Aminomethylene pyrazolones with therapeutic activity
EP2636673A1 (en) * 2012-03-06 2013-09-11 Compound Handling B.V. Aminomethylene pyrazolones with therapeutic activity
GB201208178D0 (en) 2012-05-10 2012-06-20 Summit Corp Plc Pharmaceutical composition for the treatment of duchenne muscular dystrophy
BR112014030940B1 (pt) * 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
CA2888369A1 (en) 2012-10-17 2014-04-24 F. Hoffmann-La Roche Ag 6-aminoindole derivatives as trp channel antagonists
ITMI20122065A1 (it) * 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
WO2014116859A1 (en) * 2013-01-23 2014-07-31 The University Of Chicago Methods and compositions for inhibiting human copper trafficking proteins atox1 and ccs
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
US10081629B2 (en) * 2014-04-14 2018-09-25 Jiangsu Hengrui Medicine Co., Ltd. Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
WO2016021706A1 (ja) * 2014-08-08 2016-02-11 カズマパートナーズ株式会社 縮合複素環化合物
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9371314B2 (en) 2014-10-09 2016-06-21 Allergan, Inc. Pyridyl benzothiophenes as kinase inhibitors
US9957241B2 (en) * 2015-03-31 2018-05-01 Seika Corporation Aromatic diamine, an intermediate therefor, a method for producing the aromatic diamine, and a method for producing the intermediate therefor
JP6603035B2 (ja) * 2015-03-31 2019-11-06 セイカ株式会社 アミノ基及び／又はニトロ基を有するベンゾオキサゾール−２−イル−ジフェニルエーテル及びその誘導体、並びにこれらの製造方法
JP6603043B2 (ja) * 2015-05-26 2019-11-06 セイカ株式会社 芳香族ジアミン及びその中間体、並びにこれらの製造方法
JP6802194B2 (ja) 2015-06-22 2020-12-16 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｎａｄｐｈオキシダーゼ４阻害剤
WO2017049165A1 (en) * 2015-09-18 2017-03-23 The Scripps Research Institute Rna-focused small molecules for inhibiting rna toxicity in myotonic dystrophy
EP3500245A1 (en) 2016-03-30 2019-06-26 Summit (Oxford) Limited Composition for the treatment of duchenne muscular dystrophy
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
CN113195084B (zh) * 2018-10-10 2024-04-09 阿尔伯爱因斯坦医学院 可用作分子伴侣介导的自噬调节剂的苯并噁唑及相关化合物
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
KR102132459B1 (ko) 2019-10-02 2020-07-09 손영재 알루미늄 커튼월 구조
EP4259607A1 (en) * 2020-12-11 2023-10-18 Tmem16A Limited Benzimidazole derivatives for treating respiratory disease
TW202320796A (zh) 2021-08-11 2023-06-01 美商拜歐米富士恩股份有限公司 用於糖尿病的menin-mll相互作用之共價抑制劑
US12018032B2 (en) 2021-08-20 2024-06-25 Biomea Fusion, Inc. Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction
CN114057662A (zh) * 2021-12-10 2022-02-18 湖南第一师范学院 一种Tafamidis的合成方法
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
CN121843919A (zh) 2023-09-13 2026-04-10 苏文生命科学有限公司 作为p2x7受体拮抗剂的n-芳基苯甲酰胺衍生物
CN117964572A (zh) * 2024-03-01 2024-05-03 浙江鼎龙科技股份有限公司 2-(2-羟基-4-氨基苯基)-5-氨基苯并噁唑的制备方法
EP4620957A1 (en) * 2024-03-22 2025-09-24 Eberhard Karls Universität Tübingen Imidazo[4,5-b]pyridin-7-amine compounds binding aurora kinase a and uses thereof

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE628696A (https=) * 1962-02-21
CH561242A5 (https=) 1971-08-10 1975-04-30 Ciba Geigy Ag
US3993659A (en) 1971-08-10 1976-11-23 Ciba-Geigy Corporation Bis-benzoxazolyl-naphthalenes as optical brighteners
GB1488003A (en) * 1973-10-23 1977-10-05 Lilly Industries Ltd 1,2-benzisoxazole derivatives processes for their preparation and their use as pharmaceuticals
CH617809GA3 (https=) 1975-10-10 1980-06-30
DE2619547A1 (de) * 1976-05-04 1977-11-24 Dynamit Nobel Ag Verfahren zur herstellung von 2-aryl- benzoxazolen und 2-aryl-benzthiazolen
US4110246A (en) 1976-05-13 1978-08-29 Hoechst Aktiengesellschaft Mixture of benzoxazole derivatives
DE3027479A1 (de) 1980-07-19 1982-03-04 Hoechst Ag, 6000 Frankfurt Mischungen von optischen aufhellern und deren verwendung
JPS615071A (ja) 1984-06-15 1986-01-10 Fuji Photo Film Co Ltd ベンゾオキサゾ−ル誘導体
DE3617451A1 (de) 1986-05-23 1987-11-26 Hoechst Ag Sulfonat- oder sulfonamidgruppen-haltige bis-benzoxazolylnaphthaline, verfahren zu deren herstellung und deren verwendung
JP2615805B2 (ja) 1988-04-15 1997-06-04 ミノルタ株式会社 感光体
DE3819051A1 (de) 1988-06-04 1989-12-07 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial
JPH0369292A (ja) 1989-08-08 1991-03-25 Sharp Corp スロー再生における縦揺れ補正装置
EP0527704B1 (de) 1991-08-08 1996-08-28 Ciba-Geigy Ag Farbstoffe, Verfahren zu deren Herstellung und deren Verwendung
ES2157268T5 (es) 1994-02-24 2004-12-01 SYMRISE GMBH & CO KG Preparados cosmeticos y dermatologicos que contienen acidos fenilen-1,4-bisbencimidazolsulfonicos.
US6004719A (en) 1994-04-25 1999-12-21 Polaroid Corporation Imaging medium and process for producing an image
US5596025A (en) 1994-06-30 1997-01-21 Minnesota Mining And Manufacturing Company Dental impression material with cure-indicating dye
CA2192188C (en) 1994-06-30 2008-08-19 Joel D. Oxman Cure-indicating molding and coating composition
JPH0815917A (ja) 1994-07-01 1996-01-19 Mitsubishi Chem Corp 静電荷像現像用帯電制御剤
JPH08175992A (ja) 1994-12-21 1996-07-09 Sagami Chem Res Center 神経成長因子産生促進剤および縮環型オキサゾール化合物
JP3216458B2 (ja) * 1994-12-28 2001-10-09 富士レビオ株式会社 アミド誘導体
US5567843A (en) 1995-03-20 1996-10-22 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid)azoles and 2-aminoaryl aminobenz(ox, thi, imid)azoles
US6222044B1 (en) 1995-03-20 2001-04-24 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid) azoles and 2-aminoaryl aminobenz (ox, thi, imid) azoles
US5977101A (en) 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
JP3069292B2 (ja) 1996-06-13 2000-07-24 株式会社分子バイオホトニクス研究所 カテコール化合物及びバニリル化合物の蛍光検出用固相化試薬および検出方法
US5645948A (en) 1996-08-20 1997-07-08 Eastman Kodak Company Blue organic electroluminescent devices
US6110638A (en) 1996-11-27 2000-08-29 Polaroid Corporation Process and composition for generation of acid
US5914213A (en) 1996-11-27 1999-06-22 Polaroid Corporation Process and composition for generation of acid
FR2757389B1 (fr) 1996-12-24 1999-02-05 Oreal Composition cosmetique filtrante
US6177572B1 (en) 1997-08-20 2001-01-23 Sepracor, Inc. Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use
WO1999016761A1 (fr) 1997-09-30 1999-04-08 Mitsubishi Chemical Corporation Derives heterocycliques oxygenes
JPH11171881A (ja) 1997-09-30 1999-06-29 Mitsubishi Chemical Corp 含酸素複素環誘導体
US6312822B1 (en) 1998-05-28 2001-11-06 Eastman Chem Co Dispersion aids for optical brighteners in polyolefins
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6436558B1 (en) 1998-08-07 2002-08-20 Fuji Photo Film Co., Ltd. Organic electroluminescence element
SE9804465D0 (sv) 1998-12-22 1998-12-22 Amersham Pharm Biotech Ab A method for the removal/purification of serum albumins and means for use in the method
FR2789581B1 (fr) 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de benzotriazole, un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
FR2789582B1 (fr) 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
EP1177179A1 (de) 1999-05-07 2002-02-06 Basf Aktiengesellschaft Benzoheterocyclylcyclohexenone und ihre verwendung als herbizide
DE50003732D1 (de) 1999-05-07 2003-10-23 Basf Ag 4-(3',4'-heterocyclylbenzoyl)pyrazole als herbizide
FR2794645B1 (fr) 1999-06-08 2001-08-10 Oreal Compositions photoprotectrices contenant un compose hydrocarbone bis-hydroxyphenylbenzotriazole et un compose a groupements benzoazolyle ou benzodiazolyle
JP2001039034A (ja) 1999-08-03 2001-02-13 Mitsui Chemicals Inc 光記録媒体
GB2353038A (en) 1999-08-12 2001-02-14 Eastman Chem Co Polyolefin composition comprising non-migrating optical brightener
AU7320100A (en) 1999-09-24 2001-04-24 Ono Pharmaceutical Co. Ltd. Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient
US6565987B2 (en) 1999-11-12 2003-05-20 Eastman Chemical Company Non-exuding optically brightened polyolefin blends
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
JP2001261664A (ja) 2000-03-15 2001-09-26 Konica Corp ハロゲン化銀写真感光材料、画像形成方法並びに化合物及びその合成方法
JP2002047278A (ja) 2000-08-02 2002-02-12 Fuji Photo Film Co Ltd チオエーテル化合物の製造方法
RU2324686C2 (ru) 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
US6716413B1 (en) 2000-10-16 2004-04-06 Mallinckrodt, Inc. Indole compounds as tissue-specific exogenous optical agents
EP1889891B1 (en) 2000-11-30 2017-11-22 Canon Kabushiki Kaisha Luminescence device and display apparatus
FR2818142B1 (fr) 2000-12-18 2003-12-26 Oreal Compositions antisolaires a base d'un base melange synergetique de filtres et utilisations
JP2003005356A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US20050261298A1 (en) 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
DK1482931T3 (da) 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
JP4294917B2 (ja) 2002-07-02 2009-07-15 三井化学株式会社 光記録媒体およびオキサゾール化合物
EP1547996A4 (en) 2002-08-30 2006-08-02 Bf Res Inst Inc DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES IN WHICH PRION PROTEIN IS ACCUMULATED, AND ANIMAL FEVERING FOR PRION PROTEIN
US7622592B2 (en) * 2002-11-01 2009-11-24 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
WO2004069394A2 (en) 2003-02-03 2004-08-19 The Trustees Of Columbia University In The City Of New York Synthetic method for direct arylation of heterocyclic arenes
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004103960A2 (en) 2003-05-16 2004-12-02 Ambit Biosciences Corporation Compounds and uses thereof
WO2005000295A1 (en) 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
CN1882879B (zh) 2003-09-22 2010-08-11 爱克发印艺公司 可光聚合的组合物
US7097888B2 (en) 2003-12-15 2006-08-29 Eastman Kodak Company Aligned liquid crystal layer containing azolium salts and process for increasing the tilt
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
CA2555313A1 (en) 2004-02-06 2005-08-18 Insight Biopharmaceuticals Ltd Heparanase inhibitors and uses thereof
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
US20070258912A1 (en) 2004-08-09 2007-11-08 Werner Holzl Use of Fluorescent Whitening Agents as Antimicrobials
EP1794255B1 (en) 2004-08-19 2016-11-16 LG Chem, Ltd. Organic light-emitting device comprising buffer layer and method for fabricating the same
EP2402323A3 (en) * 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
BRPI0406040B1 (pt) 2004-10-21 2018-09-11 Universidade Federal Do Rio De Janeiro - Ufrj compostos capazes de absorver radiação ultravioleta, composições contendo os mesmos e processos para sua preparação
WO2006051410A1 (en) 2004-11-15 2006-05-18 Pfizer Inc. Azabenzoxazoles for the treatment of cns disorders
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
WO2006094235A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
EP1853610A1 (en) * 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
US20060223849A1 (en) 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
DK1910384T3 (da) 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
FR2889700B1 (fr) 2005-08-11 2012-11-23 Synthinnove Lab Marqueurs, leur procede de fabrication et leurs applications
JP2007086165A (ja) 2005-09-20 2007-04-05 Fujifilm Corp 感光性組成物、これを用いた平版印刷版原版及び画像記録方法
KR100890862B1 (ko) 2005-11-07 2009-03-27 주식회사 엘지화학 유기 발광 소자 및 이의 제조 방법
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
KR101408026B1 (ko) 2005-12-02 2014-06-20 사켐,인코포레이티드 음이온-교환 치환 크로마토그래피 공정 및 음이온-교환치환 크로마토그래피 공정에서 디스플레이서 화합물들로서사용하기 위한 음이온성 유기 화합물들
KR101213485B1 (ko) 2006-01-27 2012-12-18 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
KR101213486B1 (ko) 2006-02-02 2012-12-20 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
CA2641880C (en) 2006-02-10 2014-09-09 Summit Corporation Plc Treatment of duchenne muscular dystrophy
US20090221564A1 (en) 2006-02-21 2009-09-03 Trigen Limited Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease
JP4649645B2 (ja) 2006-03-10 2011-03-16 独立行政法人科学技術振興機構 光学活性アルコール化合物の製法
KR101325062B1 (ko) 2006-05-19 2013-11-05 삼성디스플레이 주식회사 발광 이종 핵 구리-이리듐 착체 및 이를 이용한 유기 전계발광 소자
CA2691214A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy

Also Published As

Publication number Publication date
US20090075938A1 (en) 2009-03-19
CA2641880A1 (en) 2007-08-16
NZ570625A (en) 2011-10-28
DK1986633T3 (da) 2014-11-03
US8518980B2 (en) 2013-08-27
KR20130129476A (ko) 2013-11-28
US20140018320A1 (en) 2014-01-16
BRPI0707719A2 (pt) 2011-05-10
IL228598A0 (en) 2013-12-31
KR101472248B1 (ko) 2014-12-16
WO2007091106A2 (en) 2007-08-16
JP2009526034A (ja) 2009-07-16
MX2008010187A (es) 2008-10-31
AU2007213451B2 (en) 2013-02-07
WO2007091106A3 (en) 2008-03-06
JP5376956B2 (ja) 2013-12-25
SI1986633T1 (sl) 2015-03-31
CA2641880C (en) 2014-09-09
PT1986633E (pt) 2014-11-05
CY1115657T1 (el) 2017-01-25
PL1986633T3 (pl) 2015-01-30
HK1125577A1 (en) 2009-08-14
KR101426093B1 (ko) 2014-08-01
IL193315A0 (en) 2009-09-22
ES2522290T3 (es) 2014-11-14
EP1986633B1 (en) 2014-07-30
KR20090010025A (ko) 2009-01-28
EP1986633A2 (en) 2008-11-05
AU2007213451A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
IL193315A (en) 5 - (Ethylsulfonyl) -2 - (Naphthalene-2-ram) benzo [d] oxazole and use in the treatment of muscular dystrophy or muscular dystrophy
IL193314A0 (en) Treatment of duchenne muscular dystrophy
SI1978947T1 (sl) Nitrooksiderivati za uporabo pri zdravljenju mišičnih distrofij
IL192548A (en) Nitazoxanide and tizaxanide for use in the treatment of hepatitis c
EP2032186A4 (en) PORTABLE EXTRACTION TIP AND APPROPRIATE PROCEDURES
EP2007385A4 (en) CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
LT2170396T (lt) Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui
GB0715087D0 (en) Drug combinations for the treatment of duchenne muscular dystrophy
EP2337464A4 (en) DISPOSABLE GLOVE AND APPARATUS FOR THREADING A GLOVE ON THE HAND OF A USER
EP2289484A4 (en) SURFACE-TREATED POWDER AND COSMETICS THEREWITH
EP1999446A4 (en) DEVICE AND METHOD FOR LEAKAGE DETECTION IN BIOLOGICAL TREATMENT BAGS
EP2778156B8 (en) Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
ZA200806986B (en) Treatment of duchenne muscular dystrophy
EP2099299A4 (en) OXAZOLIDINONE DERIVATIVES AND METHOD FOR THEIR USE
MX2009011916A (es) Preparacion de un compuesto para el tratamiento de distrofia muscular de duchenne.
IL201426A (en) Drug combination and its use in the treatment of muscle loss
PL2003977T3 (pl) Zestaw i kompozycja do impregnacji wyrobów celulozowych
ZA200904755B (en) Use of epothilones in the treatment of osteoporosis and related diseases
GB0602767D0 (en) Treatment of muscular dystrophy
GB0623983D0 (en) Treatment of duchenne muscular dystrophy
GB0619282D0 (en) Treatment of duchenne muscular dystrophy
GB0617737D0 (en) Treatment of duchenne muscular dystrophy
GB0617740D0 (en) Treatment of duchenne muscular dystrophy
GB0623984D0 (en) Treatment of duchenne muscular dystrophy
GB0623985D0 (en) Treatment of duchenne muscular dystrophy

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees